{"id":981677,"date":"2026-07-15T08:00:08","date_gmt":"2026-07-15T12:00:08","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/acumen-pharmaceuticals-highlights-enhanced-brain-delivery-ebd-program-data-and-early-alzheimers-disease-insights-at-the-alzheimers-association-international-confe\/"},"modified":"2026-07-15T08:00:08","modified_gmt":"2026-07-15T12:00:08","slug":"acumen-pharmaceuticals-highlights-enhanced-brain-delivery-ebd-program-data-and-early-alzheimers-disease-insights-at-the-alzheimers-association-international-confe","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/acumen-pharmaceuticals-highlights-enhanced-brain-delivery-ebd-program-data-and-early-alzheimers-disease-insights-at-the-alzheimers-association-international-confe\/","title":{"rendered":"Acumen Pharmaceuticals Highlights Enhanced Brain Delivery\u2122 (EBD\u2122) Program Data and Early Alzheimer\u2019s Disease Insights at the Alzheimer\u2019s Association International Conference (AAIC\u00ae) 2026"},"content":{"rendered":"<div class=\"mw_release\">\n<ul>\n<li>EBD\u2122 bispecific antibodies targeting both A\u03b2Os and hTfR showed improved brain penetration compared to the native anti-A\u03b2O antibodies, which may enable administration with a low-volume delivery device and reduce the delivered dose required for efficacy<\/li>\n<li>EBD candidate ACU401 achieves up to 40-fold greater frontal cortex exposure in non-human primates and significant increase in exposures in deep brain regions<\/li>\n<li>No hematological safety signals observed in non-human primates, demonstrating low potential for anemia<\/li>\n<li>ALTITUDE-AD patient experience data highlight unmet need in early Alzheimer&#8217;s disease<\/li>\n<\/ul>\n<p align=\"justify\">NEWTON, Mass., July  15, 2026  (GLOBE NEWSWIRE) &#8212; Acumen Pharmaceuticals, Inc.\u00a0(NASDAQ: ABOS) (Acumen), a clinical-stage biopharmaceutical company developing novel therapeutics that target soluble amyloid beta oligomers (A\u03b2Os) for the treatment of Alzheimer\u2019s disease (AD),\u00a0today announced new findings presented at the Alzheimer&#8217;s Association International Conference (AAIC<sup>\u00ae<\/sup>) 2026 in London. Following collaboration with JCR Pharmaceuticals Co., Ltd. (JCR) on EBD candidate development, studies demonstrated improved brain penetration of anti-A\u03b2O antibodies through transferrin receptor-mediated delivery across both mouse and non-human primate models. Additionally, research from early symptomatic AD patients highlighted the lived experience among ALTITUDE-AD trial participants and their study partners.<\/p>\n<p align=\"justify\">\u201cConfirming our mouse data in non-human primates is a pivotal step for our EBD program,&#8221; said Paul Shughrue, PhD, Vice President, Program Leader and Head of Research, Acumen Pharmaceuticals. \u201cThe degree of brain penetration we observed in cynomolgus monkeys, combined with preserved soluble amyloid beta oligomer selectivity and a clean hematological profile, exceeded our expectations and gives us strong confidence in the differentiated potential of our EBD program\u2019s approach.\u201d<\/p>\n<p align=\"justify\">Acumen\u2019s presentation details are as follows:<\/p>\n<p align=\"justify\">\n        <strong>Utilizing the Transferrin Receptor-Mediated Transport System for Enhanced Brain Delivery of anti-A\u03b2 Oligomer Antibodies<\/strong>\n      <\/p>\n<p align=\"justify\">To evaluate transferrin receptor (TfR)-mediated brain delivery, Acumen and JCR developed and characterized anti-A\u03b2O antibody fusion proteins incorporating J-Brain Cargo<sup>\u00ae<\/sup>, JCR\u2019s clinically validated platform targeting the TfR, to facilitate brain uptake in humanized TfR mice. Fusion with anti-TfR fragments did not alter A\u03b2O affinity or selectivity. All EBD constructs achieved substantially higher brain levels than native anti-A\u03b2O antibodies, with each construct displaying a unique pharmacokinetic profile. Systemic absorption was confirmed after subcutaneous dosing and constructs retained the ability to bind A\u03b2 species of interest in human AD brain tissue. These findings support the continued advancement of lead EBD candidates and efforts to advance a construct to clinical trials.<\/p>\n<p align=\"justify\">\n        <strong>Bispecific Antibodies that Bind A\u03b2 Oligomers and Transferrin Receptors Show Enhanced Brain Delivery in Cynomolgus Monkeys<\/strong>\n      <\/p>\n<p align=\"justify\">In collaboration with JCR, Acumen evaluated three bispecific antibodies fusing anti-A\u03b2O antibody (ACU234) with anti-TfR antibody fragments in cynomolgus monkeys. After intravenous dosing, all three bispecific antibodies achieved greater brain exposure than ACU234 alone, with at least 14-fold higher levels in the frontal cortex. Candidate molecule ACU401 demonstrated particularly robust brain penetration: 22-fold higher at 3 hours and 40-fold higher at 24 hours in the frontal cortex, with similar trends observed in the hippocampus and putamen. No hematological findings suggestive of anemia were observed. These results, together with evidence of systemic absorption after subcutaneous dosing, highlight the potential of EBD molecules for further development in early AD.<\/p>\n<p align=\"justify\">\n        <strong>Understanding Early Symptomatic Alzheimer\u2019s Disease Through Patient Perspectives: Findings from the ALTITUDE-AD Clinical Trial Population<\/strong>\n      <\/p>\n<p align=\"justify\">Semi-structured interviews were conducted with 38 participants and their study partners prior to treatment in the ALTITUDE-AD Phase 2 study. Participants described pervasive memory-related challenges including forgetfulness, difficulty completing tasks, and communication difficulties. Emotional impacts, frustration, worry, and reduced confidence contributed to social withdrawal and reduced activity participation. Participants also reported actively managing others\u2019 perceptions of their symptoms through masking and selective disclosure. Together, results illustrate the diverse ways individuals with early Alzheimer&#8217;s disease experience, respond to, and cope with cognitive and functional changes, underscoring the importance of capturing patient experience directly to better understand meaningful benefit at this stage of disease.<\/p>\n<p align=\"justify\">\u201cTwo of the most persistent challenges in Alzheimer&#8217;s drug development are getting therapeutics where they need to go in the brain and truly understanding what matters to patients living with the disease,\u201d said Eric Siemers, M.D., Chief Medical Officer of Acumen Pharmaceuticals. \u201cThe data we&#8217;ve presented at AAIC speaks directly to both. Our collaborative work with JCR continues to push the boundaries of what&#8217;s possible with brain delivery, while our patient experience findings remind us why this work matters so deeply.\u201d<\/p>\n<p>The data posters presented will be available on the Company\u2019s website at: <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=RHqeFH7WoAjBsvPV5yqvtoEogUMnBj0XC4rgP2sKADcczvlwl-amortm9KYQTlyIooThL2f8jufkffguVQB3-twLkn1u0IB3uJUgacjbADzv_lY_r1Wl_l__vFSfdxoztaKSSdztcvrq-1rtbuYmmQ==\" rel=\"nofollow\" target=\"_blank\">https:\/\/acumenpharm.com\/publications\/<\/a>.<\/p>\n<p align=\"justify\">\n        <strong>About Sabirnetug (ACU193)<\/strong>\n      <\/p>\n<p align=\"justify\">Sabirnetug (ACU193) is a humanized monoclonal antibody (mAb) discovered and developed based on its selectivity for soluble amyloid beta oligomers (A\u03b2Os), which are a highly toxic and pathogenic form of A\u03b2, relative to A\u03b2 monomers and amyloid plaques. Soluble A\u03b2Os have been observed to be potent neurotoxins that bind to neurons, inhibit synaptic function and induce neurodegeneration. By selectively targeting toxic soluble A\u03b2Os, sabirnetug aims to address the hypothesis that soluble A\u03b2Os are an early and persistent underlying cause of the neurodegenerative process in Alzheimer\u2019s disease (AD). Sabirnetug has been granted Fast Track designation for the treatment of early AD by the U.S. Food and Drug Administration and is currently being evaluated in a Phase 2 study in patients with early AD.<\/p>\n<p align=\"justify\">\n        <strong>About ALTITUDE-AD (Phase 2)<\/strong>\n      <\/p>\n<p align=\"justify\">Initiated in 2024, ALTITUDE-AD is a Phase 2, multi-center, randomized, double-blind, placebo-controlled clinical trial designed to evaluate the efficacy and safety of sabirnetug (ACU193) infusions administered once every four weeks in slowing cognitive and functional decline as compared to placebo in participants with early Alzheimer&#8217;s disease. The study has enrolled 542 individuals with early Alzheimer\u2019s disease (mild cognitive impairment or mild dementia due to AD) at multiple investigative sites located in the United States, Canada, the European Union and the United Kingdom. Topline results are expected in late 2026. More information can be found on www.clinicaltrials.gov, NCT identifier NCT06335173.<\/p>\n<p align=\"justify\">\n        <strong>About Acumen Pharmaceuticals, Inc.<\/strong>\n      <\/p>\n<p align=\"justify\">Acumen Pharmaceuticals is a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta oligomers (A\u03b2Os) for the treatment of Alzheimer\u2019s disease (AD). Acumen\u2019s scientific founders pioneered research on A\u03b2Os, which a growing body of evidence indicates are early and persistent triggers of Alzheimer\u2019s disease pathology. Acumen is currently focused on advancing its investigational product candidate, sabirnetug (ACU193), a humanized monoclonal antibody that selectively targets toxic soluble A\u03b2Os, in its ongoing Phase 2 clinical trial ALTITUDE-AD (NCT06335173) in early symptomatic AD, following positive results in its Phase 1 trial INTERCEPT-AD. Acumen is investigating a subcutaneous formulation of sabirnetug using Halozyme\u2019s proprietary ENHANZE<sup>\u00ae<\/sup> drug delivery technology. Acumen is also collaborating with JCR Pharmaceuticals to develop an Enhanced Brain Delivery\u2122 (EBD\u2122)-enabled therapy for Alzheimer\u2019s disease utilizing a transferrin-receptor-targeting blood-brain barrier-penetrating technology. The company is headquartered in Newton, Mass. For more information, visit <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=B-6hLg8jhZloTiMOWaXdOV9c0qKvk0SNVDM6Wjey0Fjkp8zVidt95I9Hz1MDWkC3AI1RUSYPEXHYtrMFi-Pko0arWeCkG2mH6ETJtKCFGjM=\" rel=\"nofollow\" target=\"_blank\">www.acumenpharm.com<\/a>.<\/p>\n<p align=\"justify\">\n        <strong>About the J-Brain Cargo<sup>\u00ae<\/sup> Platform Technology<\/strong>\n      <\/p>\n<p align=\"justify\">JCR Pharmaceuticals has developed a proprietary blood-brain barrier (BBB)-penetrating technology, J-Brain Cargo<sup>\u00ae<\/sup>, to bring biotherapeutics into the central nervous system (CNS). The first drug developed based on this technology is IZCARGO\u2122 (INN: pabinafusp alfa) and is approved in Japan for the treatment of a lysosomal storage disorder.<\/p>\n<p>\n        <strong>About JCR Pharmaceuticals Co., Ltd.<\/strong><br \/>\n        \n      <\/p>\n<p align=\"justify\">JCR Pharmaceuticals Co., Ltd. is a global specialty pharmaceutical company that develops treatments that go beyond rare diseases to solve the world\u2019s most complex healthcare challenges. JCR continues to build upon our 50-year legacy in Japan while expanding our global footprint into the US, Europe, and Latin America. JCR\u2019s innovative therapies in Japan address conditions like growth disorder, MPS II (Hunter syndrome), Fabry disease, acute graft-versus-host disease, and renal anemia. JCR is also advancing the global development for rare diseases like MPS I (Hurler, Hurler-Scheie and Scheie syndrome), MPS II, MPS IIIA and B (Sanfilippo syndrome type A and B), and more. For more information, visit <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=RHqeFH7WoAjBsvPV5yqvtlNQZOKy4XOUSHgCZUhTGqc4UBcp2ajPct01vEBrBR-xCElkNkXTVwX7FoWJtiff_l8sZks3Kh6F3GTxFzjyckg=\" rel=\"nofollow\" target=\"_blank\">https:\/\/jcrpharm.com\/<\/a>.<\/p>\n<p align=\"justify\">\n        <strong>Forward-Looking Statements<\/strong>\n      <\/p>\n<p align=\"justify\">This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Any statement describing Acumen\u2019s goals, expectations, financial or other projections, intentions or beliefs is a forward-looking statement and should be considered an at-risk statement. Words such as \u201cbelieves,\u201d \u201cexpects,\u201d \u201canticipates,\u201d \u201ccould,\u201d \u201cshould,\u201d \u201cwould,\u201d \u201cseeks,\u201d \u201caims,\u201d \u201cplans,\u201d \u201cpotential,\u201d \u201cwill,\u201d \u201cmilestone\u201d and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Forward-looking statements include statements concerning Acumen\u2019s business, the therapeutic potential of Acumen\u2019s product candidate, sabirnetug (ACU193) and ACU 234, and the potential to develop a candidate to treat Alzheimer&#8217;s Disease utilizing EBD technology. These statements are based upon the current beliefs and expectations of Acumen management, and are subject to certain factors, risks and uncertainties, particularly those inherent in the process of discovering, developing and commercializing safe and effective human therapeutics. Such risks may be amplified by the impacts of geopolitical events and macroeconomic conditions, such as rising inflation and interest rates, supply disruptions and uncertainty of credit and financial markets. These and other risks concerning Acumen\u2019s programs are described in additional detail in Acumen\u2019s filings with the Securities and Exchange Commission (\u201cSEC\u201d), including in Acumen\u2019s most recent Annual Report on Form 10-K, and in subsequent filings with the SEC. Copies of these and other documents are available from Acumen. Additional information will be made available in other filings that Acumen makes from time to time with the SEC. These forward-looking statements speak only as of the date hereof, and Acumen expressly disclaims any obligation to update or revise any forward-looking statement, except as otherwise required by law, whether, as a result of new information, future events or otherwise.<\/p>\n<p>\n        <strong>Investors:<\/strong><br \/>\n        <br \/>Alex Braun<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=BavICu1K0R_KBrhUFNrh4MblgQ51d__rdv9hj_BBuNjiPSsMFe9M6xFzn_bd8CL-k-IqBZXfNKcKhY7nYNEkqFzx3Il015nS7ElYm6buDU8=\" rel=\"nofollow\" target=\"_blank\">abraun@acumenpharm.com<\/a>\u00a0<\/p>\n<p>\n        <strong>Media:<\/strong><br \/>\n        <br \/>ICR Healthcare<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=hJTA_ewYLk97zsOoq7IUFY-nk4oGwQ-9WEAOAGOKH1rQORblUY0qrhKXi6OMV8L3CUBscvpZ6H4uKESx1pmori90TgrNa29--412GcNp7PJMDEMkgl63c9uJL87Qn_JK\" rel=\"nofollow\" target=\"_blank\">AcumenPR@icrhealthcare.com<\/a>\u00a0<\/p>\n<p>      <img decoding=\"async\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTc2MjE4OSM3NzA1ODgyIzIyMTA2ODI=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" alt=\"\" src=\"https:\/\/ml.globenewswire.com\/media\/NjAwNjBlNTUtYTQ4My00ODBhLWFjOTQtMzRlOWU5MmZkZjg0LTEyMjIyMzUtMjAyNi0wNy0xNS1lbg==\/tiny\/Acumen-Pharmaceuticals-Inc-.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>EBD\u2122 bispecific antibodies targeting both A\u03b2Os and hTfR showed improved brain penetration compared to the native anti-A\u03b2O antibodies, which may enable administration with a low-volume delivery device and reduce the delivered dose required for efficacy EBD candidate ACU401 achieves up to 40-fold greater frontal cortex exposure in non-human primates and significant increase in exposures in deep brain regions No hematological safety signals observed in non-human primates, demonstrating low potential for anemia ALTITUDE-AD patient experience data highlight unmet need in early Alzheimer&#8217;s disease NEWTON, Mass., July 15, 2026 (GLOBE NEWSWIRE) &#8212; Acumen Pharmaceuticals, Inc.\u00a0(NASDAQ: ABOS) (Acumen), a clinical-stage biopharmaceutical company developing novel therapeutics that target soluble amyloid beta oligomers (A\u03b2Os) for the treatment of Alzheimer\u2019s disease (AD),\u00a0today announced new findings presented &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/acumen-pharmaceuticals-highlights-enhanced-brain-delivery-ebd-program-data-and-early-alzheimers-disease-insights-at-the-alzheimers-association-international-confe\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Acumen Pharmaceuticals Highlights Enhanced Brain Delivery\u2122 (EBD\u2122) Program Data and Early Alzheimer\u2019s Disease Insights at the Alzheimer\u2019s Association International Conference (AAIC\u00ae) 2026&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-981677","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.0 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Acumen Pharmaceuticals Highlights Enhanced Brain Delivery\u2122 (EBD\u2122) Program Data and Early Alzheimer\u2019s Disease Insights at the Alzheimer\u2019s Association International Conference (AAIC\u00ae) 2026 - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/acumen-pharmaceuticals-highlights-enhanced-brain-delivery-ebd-program-data-and-early-alzheimers-disease-insights-at-the-alzheimers-association-international-confe\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Acumen Pharmaceuticals Highlights Enhanced Brain Delivery\u2122 (EBD\u2122) Program Data and Early Alzheimer\u2019s Disease Insights at the Alzheimer\u2019s Association International Conference (AAIC\u00ae) 2026 - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"EBD\u2122 bispecific antibodies targeting both A\u03b2Os and hTfR showed improved brain penetration compared to the native anti-A\u03b2O antibodies, which may enable administration with a low-volume delivery device and reduce the delivered dose required for efficacy EBD candidate ACU401 achieves up to 40-fold greater frontal cortex exposure in non-human primates and significant increase in exposures in deep brain regions No hematological safety signals observed in non-human primates, demonstrating low potential for anemia ALTITUDE-AD patient experience data highlight unmet need in early Alzheimer&#8217;s disease NEWTON, Mass., July 15, 2026 (GLOBE NEWSWIRE) &#8212; Acumen Pharmaceuticals, Inc.\u00a0(NASDAQ: ABOS) (Acumen), a clinical-stage biopharmaceutical company developing novel therapeutics that target soluble amyloid beta oligomers (A\u03b2Os) for the treatment of Alzheimer\u2019s disease (AD),\u00a0today announced new findings presented &hellip; Continue reading &quot;Acumen Pharmaceuticals Highlights Enhanced Brain Delivery\u2122 (EBD\u2122) Program Data and Early Alzheimer\u2019s Disease Insights at the Alzheimer\u2019s Association International Conference (AAIC\u00ae) 2026&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/acumen-pharmaceuticals-highlights-enhanced-brain-delivery-ebd-program-data-and-early-alzheimers-disease-insights-at-the-alzheimers-association-international-confe\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2026-07-15T12:00:08+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTc2MjE4OSM3NzA1ODgyIzIyMTA2ODI=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"8 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/acumen-pharmaceuticals-highlights-enhanced-brain-delivery-ebd-program-data-and-early-alzheimers-disease-insights-at-the-alzheimers-association-international-confe\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/acumen-pharmaceuticals-highlights-enhanced-brain-delivery-ebd-program-data-and-early-alzheimers-disease-insights-at-the-alzheimers-association-international-confe\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Acumen Pharmaceuticals Highlights Enhanced Brain Delivery\u2122 (EBD\u2122) Program Data and Early Alzheimer\u2019s Disease Insights at the Alzheimer\u2019s Association International Conference (AAIC\u00ae) 2026\",\"datePublished\":\"2026-07-15T12:00:08+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/acumen-pharmaceuticals-highlights-enhanced-brain-delivery-ebd-program-data-and-early-alzheimers-disease-insights-at-the-alzheimers-association-international-confe\\\/\"},\"wordCount\":1608,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/acumen-pharmaceuticals-highlights-enhanced-brain-delivery-ebd-program-data-and-early-alzheimers-disease-insights-at-the-alzheimers-association-international-confe\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTc2MjE4OSM3NzA1ODgyIzIyMTA2ODI=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/acumen-pharmaceuticals-highlights-enhanced-brain-delivery-ebd-program-data-and-early-alzheimers-disease-insights-at-the-alzheimers-association-international-confe\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/acumen-pharmaceuticals-highlights-enhanced-brain-delivery-ebd-program-data-and-early-alzheimers-disease-insights-at-the-alzheimers-association-international-confe\\\/\",\"name\":\"Acumen Pharmaceuticals Highlights Enhanced Brain Delivery\u2122 (EBD\u2122) Program Data and Early Alzheimer\u2019s Disease Insights at the Alzheimer\u2019s Association International Conference (AAIC\u00ae) 2026 - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/acumen-pharmaceuticals-highlights-enhanced-brain-delivery-ebd-program-data-and-early-alzheimers-disease-insights-at-the-alzheimers-association-international-confe\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/acumen-pharmaceuticals-highlights-enhanced-brain-delivery-ebd-program-data-and-early-alzheimers-disease-insights-at-the-alzheimers-association-international-confe\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTc2MjE4OSM3NzA1ODgyIzIyMTA2ODI=\",\"datePublished\":\"2026-07-15T12:00:08+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/acumen-pharmaceuticals-highlights-enhanced-brain-delivery-ebd-program-data-and-early-alzheimers-disease-insights-at-the-alzheimers-association-international-confe\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/acumen-pharmaceuticals-highlights-enhanced-brain-delivery-ebd-program-data-and-early-alzheimers-disease-insights-at-the-alzheimers-association-international-confe\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/acumen-pharmaceuticals-highlights-enhanced-brain-delivery-ebd-program-data-and-early-alzheimers-disease-insights-at-the-alzheimers-association-international-confe\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTc2MjE4OSM3NzA1ODgyIzIyMTA2ODI=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTc2MjE4OSM3NzA1ODgyIzIyMTA2ODI=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/acumen-pharmaceuticals-highlights-enhanced-brain-delivery-ebd-program-data-and-early-alzheimers-disease-insights-at-the-alzheimers-association-international-confe\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Acumen Pharmaceuticals Highlights Enhanced Brain Delivery\u2122 (EBD\u2122) Program Data and Early Alzheimer\u2019s Disease Insights at the Alzheimer\u2019s Association International Conference (AAIC\u00ae) 2026\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Acumen Pharmaceuticals Highlights Enhanced Brain Delivery\u2122 (EBD\u2122) Program Data and Early Alzheimer\u2019s Disease Insights at the Alzheimer\u2019s Association International Conference (AAIC\u00ae) 2026 - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/acumen-pharmaceuticals-highlights-enhanced-brain-delivery-ebd-program-data-and-early-alzheimers-disease-insights-at-the-alzheimers-association-international-confe\/","og_locale":"en_US","og_type":"article","og_title":"Acumen Pharmaceuticals Highlights Enhanced Brain Delivery\u2122 (EBD\u2122) Program Data and Early Alzheimer\u2019s Disease Insights at the Alzheimer\u2019s Association International Conference (AAIC\u00ae) 2026 - Market Newsdesk","og_description":"EBD\u2122 bispecific antibodies targeting both A\u03b2Os and hTfR showed improved brain penetration compared to the native anti-A\u03b2O antibodies, which may enable administration with a low-volume delivery device and reduce the delivered dose required for efficacy EBD candidate ACU401 achieves up to 40-fold greater frontal cortex exposure in non-human primates and significant increase in exposures in deep brain regions No hematological safety signals observed in non-human primates, demonstrating low potential for anemia ALTITUDE-AD patient experience data highlight unmet need in early Alzheimer&#8217;s disease NEWTON, Mass., July 15, 2026 (GLOBE NEWSWIRE) &#8212; Acumen Pharmaceuticals, Inc.\u00a0(NASDAQ: ABOS) (Acumen), a clinical-stage biopharmaceutical company developing novel therapeutics that target soluble amyloid beta oligomers (A\u03b2Os) for the treatment of Alzheimer\u2019s disease (AD),\u00a0today announced new findings presented &hellip; Continue reading \"Acumen Pharmaceuticals Highlights Enhanced Brain Delivery\u2122 (EBD\u2122) Program Data and Early Alzheimer\u2019s Disease Insights at the Alzheimer\u2019s Association International Conference (AAIC\u00ae) 2026\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/acumen-pharmaceuticals-highlights-enhanced-brain-delivery-ebd-program-data-and-early-alzheimers-disease-insights-at-the-alzheimers-association-international-confe\/","og_site_name":"Market Newsdesk","article_published_time":"2026-07-15T12:00:08+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTc2MjE4OSM3NzA1ODgyIzIyMTA2ODI=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"8 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/acumen-pharmaceuticals-highlights-enhanced-brain-delivery-ebd-program-data-and-early-alzheimers-disease-insights-at-the-alzheimers-association-international-confe\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/acumen-pharmaceuticals-highlights-enhanced-brain-delivery-ebd-program-data-and-early-alzheimers-disease-insights-at-the-alzheimers-association-international-confe\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Acumen Pharmaceuticals Highlights Enhanced Brain Delivery\u2122 (EBD\u2122) Program Data and Early Alzheimer\u2019s Disease Insights at the Alzheimer\u2019s Association International Conference (AAIC\u00ae) 2026","datePublished":"2026-07-15T12:00:08+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/acumen-pharmaceuticals-highlights-enhanced-brain-delivery-ebd-program-data-and-early-alzheimers-disease-insights-at-the-alzheimers-association-international-confe\/"},"wordCount":1608,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/acumen-pharmaceuticals-highlights-enhanced-brain-delivery-ebd-program-data-and-early-alzheimers-disease-insights-at-the-alzheimers-association-international-confe\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTc2MjE4OSM3NzA1ODgyIzIyMTA2ODI=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/acumen-pharmaceuticals-highlights-enhanced-brain-delivery-ebd-program-data-and-early-alzheimers-disease-insights-at-the-alzheimers-association-international-confe\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/acumen-pharmaceuticals-highlights-enhanced-brain-delivery-ebd-program-data-and-early-alzheimers-disease-insights-at-the-alzheimers-association-international-confe\/","name":"Acumen Pharmaceuticals Highlights Enhanced Brain Delivery\u2122 (EBD\u2122) Program Data and Early Alzheimer\u2019s Disease Insights at the Alzheimer\u2019s Association International Conference (AAIC\u00ae) 2026 - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/acumen-pharmaceuticals-highlights-enhanced-brain-delivery-ebd-program-data-and-early-alzheimers-disease-insights-at-the-alzheimers-association-international-confe\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/acumen-pharmaceuticals-highlights-enhanced-brain-delivery-ebd-program-data-and-early-alzheimers-disease-insights-at-the-alzheimers-association-international-confe\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTc2MjE4OSM3NzA1ODgyIzIyMTA2ODI=","datePublished":"2026-07-15T12:00:08+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/acumen-pharmaceuticals-highlights-enhanced-brain-delivery-ebd-program-data-and-early-alzheimers-disease-insights-at-the-alzheimers-association-international-confe\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/acumen-pharmaceuticals-highlights-enhanced-brain-delivery-ebd-program-data-and-early-alzheimers-disease-insights-at-the-alzheimers-association-international-confe\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/acumen-pharmaceuticals-highlights-enhanced-brain-delivery-ebd-program-data-and-early-alzheimers-disease-insights-at-the-alzheimers-association-international-confe\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTc2MjE4OSM3NzA1ODgyIzIyMTA2ODI=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTc2MjE4OSM3NzA1ODgyIzIyMTA2ODI="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/acumen-pharmaceuticals-highlights-enhanced-brain-delivery-ebd-program-data-and-early-alzheimers-disease-insights-at-the-alzheimers-association-international-confe\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Acumen Pharmaceuticals Highlights Enhanced Brain Delivery\u2122 (EBD\u2122) Program Data and Early Alzheimer\u2019s Disease Insights at the Alzheimer\u2019s Association International Conference (AAIC\u00ae) 2026"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/981677","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=981677"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/981677\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=981677"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=981677"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=981677"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}